ES2137878B1 - PROCEDURE FOR OBTAINING AN ATTENUATED HUMAN PLASMA OF VIRUSES FOR THERAPEUTIC USE. - Google Patents

PROCEDURE FOR OBTAINING AN ATTENUATED HUMAN PLASMA OF VIRUSES FOR THERAPEUTIC USE.

Info

Publication number
ES2137878B1
ES2137878B1 ES9702496A ES9702496A ES2137878B1 ES 2137878 B1 ES2137878 B1 ES 2137878B1 ES 9702496 A ES9702496 A ES 9702496A ES 9702496 A ES9702496 A ES 9702496A ES 2137878 B1 ES2137878 B1 ES 2137878B1
Authority
ES
Spain
Prior art keywords
procedure
obtaining
therapeutic use
plasma
human plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9702496A
Other languages
Spanish (es)
Other versions
ES2137878A1 (en
Inventor
Debart Pere Ristol
Rodriguez Jesus Fernandez
Camison Maria Isabel Bravo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols SA filed Critical Grifols SA
Priority to ES9702496A priority Critical patent/ES2137878B1/en
Publication of ES2137878A1 publication Critical patent/ES2137878A1/en
Application granted granted Critical
Publication of ES2137878B1 publication Critical patent/ES2137878B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procedimiento de obtención de un plasma humano atenuado de virus para uso terapéutico. El procedimiento se caracteriza porque la mezcla del plasma tratado es estabilizado y protegida contra la degradación, siendo los restos de los reactivos empleados en el método de inactivación eliminados por adsorción con una resina selectiva, complementándose con una concentración por ultrafiltración hasta obtener un plasma cuya composición proteica es equivalente al plasma fresco congelado y es apto para su transfusión.Procedure for obtaining an attenuated virus human plasma for therapeutic use. The procedure is characterized in that the mixture of the treated plasma is stabilized and protected against degradation, the remains of the reagents used in the inactivation method being removed by adsorption with a selective resin, complemented by concentration by ultrafiltration until obtaining a plasma whose composition Protein is equivalent to fresh frozen plasma and is suitable for transfusion.

ES9702496A 1997-12-01 1997-12-01 PROCEDURE FOR OBTAINING AN ATTENUATED HUMAN PLASMA OF VIRUSES FOR THERAPEUTIC USE. Expired - Fee Related ES2137878B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9702496A ES2137878B1 (en) 1997-12-01 1997-12-01 PROCEDURE FOR OBTAINING AN ATTENUATED HUMAN PLASMA OF VIRUSES FOR THERAPEUTIC USE.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9702496A ES2137878B1 (en) 1997-12-01 1997-12-01 PROCEDURE FOR OBTAINING AN ATTENUATED HUMAN PLASMA OF VIRUSES FOR THERAPEUTIC USE.

Publications (2)

Publication Number Publication Date
ES2137878A1 ES2137878A1 (en) 1999-12-16
ES2137878B1 true ES2137878B1 (en) 2000-10-01

Family

ID=8301352

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9702496A Expired - Fee Related ES2137878B1 (en) 1997-12-01 1997-12-01 PROCEDURE FOR OBTAINING AN ATTENUATED HUMAN PLASMA OF VIRUSES FOR THERAPEUTIC USE.

Country Status (1)

Country Link
ES (1) ES2137878B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4142908C2 (en) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Method for producing a virus-inactivated prothrombin complex concentrate (PPSB)
DE4337573C1 (en) * 1993-11-04 1995-05-18 Octapharma Ag Process for the preparation of a virus-inactivated factor VIII-containing fraction by means of chromatographic methods

Also Published As

Publication number Publication date
ES2137878A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
DE69835279D1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS
ID29393A (en) COMPOSITION OF CANCER TREATMENT AND METHOD OF USING NATURAL PLANT ESENSIL OILS
AR013670A1 (en) DEVICE FOR THE TREATMENT OF VARICOSE VEINS
BR0214772A (en) systems and methods for treating patients with processed liposuction cells
ATE106740T1 (en) PREPARATION OF T-CELLS AND T-CELL MEMBRANES USABLE FOR PREVENTING AND TREATMENT OF AUTOIMMUNE DISEASES.
TR200102308T2 (en) Artificial peptides with surface activity and their use in the preparation of artificial surfactants
NO951761L (en) Stable preparation for the treatment of blood coagulation disorders
BR0113006A (en) Method for treating type II glycogen storage disease in an individual and its use
ATE260041T1 (en) METHOD FOR THE GERMINATION-INHIBITING TREATMENT OF TUBERS AND ONIONS WITH EUGENOL AND/OR ISOEUGENOL
RU94022754A (en) Method for preventing and treating ischemia attacks and reperfusion-induced injuries influenced by the attacks
DE69116380D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME
DK1201137T3 (en) Cysteine / glycine-rich peptides
FI961536A0 (en) Procedure for inactivating viruses in the presence of polyalkylene glycol and thus obtained pharmaceutical preparation
DK1001775T3 (en) Medication containing yohimbine and arginine intended to treat erectile dysfunction
DK1648496T3 (en) A method of stabilizing a cryoprecipitate of plasmatic proteins intended to be subjected to a heat treatment for virus inactivation
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
DE50108409D1 (en) TREATMENT OF SURFACES FOR THE TEMPORARY IMPROVEMENT OF DIRT-RELATED BEHAVIOR
ES2113910T3 (en) PROCEDURE FOR THE PREPARATION OF A TROMBINE CONCENTRATE INSURED AGAINST VIRUSES.
ES2137878B1 (en) PROCEDURE FOR OBTAINING AN ATTENUATED HUMAN PLASMA OF VIRUSES FOR THERAPEUTIC USE.
DE69632629D1 (en) THROMBIN COMPOSITION
DE60103658D1 (en) EX-VIVO CLL CELLS TREATED UNDER OXIDATIVE STRESS FOR TREATING CHRONIC LYMPHOCYTIC LEAUCEMY (CLL)
ATE544453T1 (en) COMBINATION THERAPIES WITH L-FMAU FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS
DE69927815D1 (en) INOSITOLPHOSPHOGLYCAN AND RIBOSE FOR THE TREATMENT OF ISCHEMIC REPERFUSION DAMAGE
EA200100223A3 (en) Water dispersed ivermectin dosage form for curing ecto- endoparasitic diseases

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991216

Kind code of ref document: A1

Effective date: 19991216

FD2A Announcement of lapse in spain

Effective date: 20180326